Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.32 Analyst target: $11.00 Upside: 231.33%
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The company is headquartered in Norcross, Georgia.
See the full interactive analysis & chart →Informational only — not investment advice.